DLQIX
Price
$15.07
Change
-$0.08 (-0.53%)
Updated
Jun 22 closing price
Net Assets
138.65M
GFACX
Price
$72.91
Change
-$0.39 (-0.53%)
Updated
Jun 22 closing price
Net Assets
360.63B
Interact to see
Advertisement

DLQIX vs GFACX

DLQIX vs GFACX Comparison Chart in %
View a ticker or compare two or three
VS
DLQIX vs. GFACX commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DLQIX is a Buy and GFACX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 361B vs. DLQIX (139M). DLQIX pays higher dividends than GFACX: DLQIX (0.52) vs GFACX (0.00). DLQIX was incepted earlier than GFACX: DLQIX (29 years) vs GFACX (25 years). GFACX (1.35) is less costly to investors than DLQIX (0.88). DLQIX is a more actively managed with annual turnover of: 38.87 vs. GFACX (32.00). GFACX has a lower initial minimum investment than DLQIX: GFACX (250) vs DLQIX (1000). GFACX annual gain was more profitable for investors over the last year : 9.31 vs. DLQIX (0.75). GFACX return over 5 years is better than : 9.24 vs. DLQIX (-47.03).
DLQIXGFACXDLQIX / GFACX
Total Expense Ratio0.751.3556%
Annual Report Gross Expense Ratio0.881.3565%
Fund Existence29 years25 years-
Gain YTD3.6258.33643%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets139M361B0%
Annual Yield % from dividends0.520.00-
Returns for 1 year0.759.318%
Returns for 3 years-22.9439.75-58%
Returns for 5 years-47.039.24-509%
Returns for 10 years-3.0192.48-3%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NMIMX30.520.03
+0.09%
Columbia Large Cap Enhanced Core Inst
CIRCX82.040.04
+0.05%
American Funds Capital Income Bldr 529C
PHLCX9.59N/A
N/A
PGIM Jennison Health Sciences C
STLYX43.71N/A
N/A
SEI Tax-Managed Large Cap Y (SIMT)
TMITX9.64N/A
N/A
Transamerica Mid Cap Growth I3